Centilo

QTc Prolongation in Children: Causes, Formulas, and Clinical Decision-Making

By Daniel Diaz-Gil, MD· April 2026 · 10 min read

Summary

  • The upper limit of normal QTc in infants and children is generally 460 ms. In children younger than 12 years, the 98th percentile is approximately 450 ms; post-pubertally, thresholds diverge by sex (>450 ms in males, >460 ms in females) [1,4].
  • QTc >500 ms carries substantially increased risk for torsades de pointes (TdP) and sudden cardiac death and requires urgent evaluation. QTc <300 ms (short QT) is also associated with malignant arrhythmia [1].
  • Bazett correction (QT/√RR) overcorrects at high heart rates and undercorrects at low heart rates. Fridericia (QT/³√RR) performs better at heart rate extremes [4,5,6].
  • Congenital long QT syndrome (LQTS) is diagnosed by Schwartz score ≥3.5, a pathogenic variant, or repeated QTc ≥500 ms without QT-prolonging drugs, not by QTc alone [12].
  • Beta-blockers are first-line therapy for LQTS (Class I for resting QTc >470 ms) [14]. Genotype determines trigger avoidance and adjunct therapy: LQT1 (exercise/swimming), LQT2 (auditory stimuli), LQT3 (rest/sleep) [10,12].
  • In patients on QT-prolonging drugs, maintain potassium ≥4.0 mEq/L and magnesium ≥2.0 mg/dL. Discontinue the offending drug if QTc exceeds 500 ms or rises ≥60 ms from baseline [17].

Open the QTc Calculator →

Normal QTc Values by Age

Age group Threshold Notes
Neonates (first week) Up to 460 ms may be normal; >470 ms warrants investigation An estimated 10% of SIDS is thought to result from hereditary QT prolongation [1]
Children (11 days to 16 years) 98th percentile ≈450 ms in children <12 years Sex differences are not yet present [4]
Adolescents, post-pubertal >450 ms (males), >460 ms (females) is prolonged Rate-adjusted QT shortens in boys at puberty, possibly a testosterone effect; girls show little change [1]

Risk stratification by QTc:

QTc Interpretation
>500 ms Substantially increased TdP and sudden cardiac death risk; urgent evaluation
460-500 ms Monitor, especially with concurrent QT-prolonging drugs or electrolyte abnormalities
<300 ms Short QT interval; also associated with malignant arrhythmia

Correction Formulas: Bazett vs. Fridericia

Formula Equation Behavior
Bazett QTc = QT / √RR Most widely used; matches most reference data and the Schwartz score; overcorrects at high heart rate, undercorrects at low heart rate [4]
Fridericia QTc = QT / ³√RR More stable at heart rate extremes [5,6,8]

Clinical pearl. In a 2020 study of 332 healthy children, postural change from supine to standing raised heart rate and moved Bazett-corrected QTc from 425 ms to 445 ms, while Fridericia-corrected QTc changed minimally. At standing, Bazett flagged 151 children with QTc 440-460 ms and 45 with QTc 460-480 ms; Fridericia flagged fewer than 7 children with QTc 440-460 ms and none higher [6].

Practical recommendations:

  • Use Bazett for routine pediatric screening when heart rate is within normal range, since most reference data and diagnostic criteria (including the Schwartz score) use Bazett correction [4,7].
  • Use Fridericia when heart rate is significantly abnormal (<60 or >90 bpm) or when Bazett-corrected QTc is borderline [5,6,8].
  • A 2025 study of 3,672 young athletes (ages 11-16) recommends using both Bazett and Fridericia for cardiovascular screening; Fridericia showed no significant differences by age in this population [9].

Caution. Bazett overcorrection at high heart rates can generate a false-positive prolonged QTc in a tachycardic infant. Confirm a borderline Bazett result with Fridericia before acting on it.

Diagnosing Congenital Long QT Syndrome: The Schwartz Score

Diagnosis should rest on a combination of QT prolongation, clinical features, and family history rather than QTc duration alone [12].

ECG findings:

Finding Points
QTc ≥480 ms 3
QTc 460-479 ms 2
QTc 450-459 ms (males) 1
QTc ≥480 ms at 4-minute recovery from exercise stress test 1
Torsades de pointes 2
T-wave alternans 1
Notched T wave in 3 leads 1
Low heart rate for age (<2nd percentile) 0.5

Clinical history:

Finding Points
Syncope with stress 2
Syncope without stress 1
Congenital deafness 0.5

Family history:

Finding Points
Family member with definite LQTS 1
Unexplained sudden cardiac death <30 years in an immediate family member 0.5

Interpretation:

Score Probability
≤1 Low
1.5-3 Intermediate
≥3.5 High (specificity 99%, sensitivity 19-36%)

LQTS is definitively diagnosed with a Schwartz score ≥3.5, a pathogenic variant, or repeated QTc ≥500 ms in the absence of QT-prolonging drugs [12].

Genotype-Phenotype Correlations

Subtype Gene, frequency Triggers Treatment notes
LQT1 KCNQ1, ~40-45% Adrenergic stimulation, strenuous exercise (especially swimming), emotional stress Beta-blockers highly effective (>95% reduction in adverse events); left cardiac sympathetic denervation (LCSD) particularly effective; ICD rarely needed for primary prevention [10,12]
LQT2 KCNH2, ~25-30% Sudden auditory stimuli (alarms, phones), emotional stress, hypokalemia Females at higher risk, particularly postpartum; maintain K+ ≥4 mmol/L; remove bedroom alarms/phones; beta-blockers morning and evening [10,12]
LQT3 SCN5A, ~5-10% Rest or sleep, often bradycardia-dependent Beta-blockers less effective; sodium channel blockers (mexiletine, ranolazine, flecainide) shorten QTc and reduce recurrence; consider home AED and bedroom sharing [10,12]

Management of Congenital LQTS

  • Beta-blocker therapy is indicated for LQTS with resting QTc >470 ms (Class I, Level B-NR) [14].
  • In asymptomatic patients with QTc <470 ms, chronic beta-blocker therapy is reasonable (Class IIa) [14].
  • For high-risk, symptomatic patients in whom beta-blockers are ineffective or not tolerated: intensify therapy with additional medications guided by LQTS type, LCSD, and/or ICD [14].
  • QT-prolonging medications are potentially harmful in LQTS (Class III: Harm) [14].
  • Genetic counseling and testing are recommended for all patients with clinically diagnosed LQTS (Class I); yield in phenotype-positive patients is 50-86% [10,13].

High-risk features: QTc ≥500 ms, LQT2 or LQT3 genotype, females with LQT2, males with LQT3, symptom onset <10 years of age, prior cardiac arrest or recurrent syncope [14].

ICD indications (2021 PACES Expert Consensus):

Recommendation Class Population
ICD indicated I Survivors of sudden cardiac arrest; symptomatic patients (arrhythmic syncope or VT) in whom beta-blockers are ineffective/not tolerated and LCSD or other medications are not effective alternatives [15,16]
ICD may be considered IIb Primary prevention with established clinical risk factors and/or pathogenic mutations [15,16]
ICD not indicated III: Harm Asymptomatic, low-risk patients not yet tried on beta-blocker therapy [15,16]

Acquired QT Prolongation

Acquired QT prolongation is more common than congenital LQTS in practice. Drug-induced TdP is rare without risk factors but can be fatal [17].

Common QT-prolonging drug classes:

Class Examples
Antiarrhythmics Sotalol, amiodarone, flecainide, dofetilide, ibutilide, procainamide, quinidine
Antipsychotics Haloperidol, thioridazine, chlorpromazine, risperidone, olanzapine, ziprasidone
Antibiotics Macrolides (azithromycin, erythromycin, clarithromycin); fluoroquinolones (levofloxacin, moxifloxacin, ciprofloxacin)
Antiemetics Ondansetron, domperidone, metoclopramide
Antidepressants Citalopram, escitalopram, tricyclic antidepressants
Other Methadone, pentamidine, chloroquine/hydroxychloroquine

[17,18]

Clinical pearl. A 2025 pediatric study found QTc prolongation (>450 ms) in 4.2-5.4% of children taking SSRIs, with a positive correlation between norfluoxetine (fluoxetine metabolite) serum levels and QTc duration [19].

Risk factors for drug-induced TdP:

  • QTc >500 ms or QTc lengthening ≥60 ms from baseline
  • Female sex
  • Bradycardia
  • Hypokalemia, hypomagnesemia, hypocalcemia
  • Heart failure
  • Concomitant use of ≥2 QT-prolonging drugs
  • History of drug-induced TdP
  • Genetic predisposition (nearly 30% of patients with drug-induced QT prolongation carry LQTS gene mutations) [17]

Electrolyte targets. Hypokalemia, hypocalcemia, and hypomagnesemia substantially amplify drug-induced QTc risk. In patients on QT-prolonging drugs, maintain serum potassium >4.0 mEq/L and magnesium >2.0 mg/dL [17].

Management sequence:

  1. Baseline ECG before starting high-risk medications.
  2. Repeat ECG at steady state (typically 3-5 days) and after dose increases.
  3. Correct electrolyte abnormalities before and during therapy.
  4. Avoid concurrent QT-prolonging agents when possible.
  5. Discontinuation thresholds: QTc >500 ms requires discontinuation unless essential for survival; QTc increase ≥60 ms from baseline warrants strong consideration for discontinuation; QTc 480-500 ms requires close monitoring, with consideration of dose reduction or an alternative agent.
  6. Maintain potassium ≥4.0 mEq/L and magnesium ≥2.0 mg/dL in patients on QT-prolonging drugs.

[17]

Monitoring

Serial ECGs are recommended for children on QT-prolonging medications or with a family history of sudden death. The AHA recommends QTc monitoring for [3]:

  • Congenital LQTS with unstable ventricular arrhythmias
  • Medically or metabolically induced QTc prolongation, until stabilization
  • Moderate to severe hypokalemia or hypomagnesemia combined with other TdP risk factors
  • Drug overdose involving agents with known TdP risk

Consult CredibleMeds for updated lists of QT-prolonging drugs.

Caution. Refer urgently any child with QTc >460 ms, syncope, and a family history of sudden death for cardiology evaluation.

References

  1. Buratti G, Shrestha S, Donne M, Katta P. Approach to Prolonged QT Interval in Paediatric and Neonatal Patients. Eur J Pediatr. 2025;184(12):778.
  2. Krahn AD, Laksman Z, Sy RW, et al. Congenital Long QT Syndrome. JACC Clin Electrophysiol. 2022;8(5):687-706.
  3. Sandau KE, Funk M, Auerbach A, et al. Update to Practice Standards for Electrocardiographic Monitoring in Hospital Settings: A Scientific Statement From the American Heart Association. Circulation. 2017;136(19):e273-e344.
  4. Rautaharju PM, Surawicz B, Gettes LS, et al. AHA/ACCF/HRS Recommendations for the Standardization and Interpretation of the Electrocardiogram: Part IV. J Am Coll Cardiol. 2009;53(11):982-991.
  5. Phan DQ, Silka MJ, Lan YT, Chang RK. Comparison of Formulas for Calculation of the Corrected QT Interval in Infants and Young Children. J Pediatr. 2015;166(4):960-964.
  6. Andrsova I, Hnatkova K, Helanova K, et al. Problems With Bazett QTc Correction in Paediatric Screening of Prolonged QTc Interval. BMC Pediatr. 2020;20(1):558.
  7. Mahendran S, Gupta I, Davis J, et al. Comparison of Methods for Correcting QT Interval in Athletes and Young People: A Systematic Review. Clin Cardiol. 2023;46(9):1106-1115.
  8. Andrsova I, Hnatkova K, Sisakova M, et al. Influence of Heart Rate Correction Formulas on QTc Interval Stability. Sci Rep. 2021;11(1):14269.
  9. Idiazabal-Ayesa U, Guia-Galipienso F, Sanz-de la Garza M, et al. Influences of Age, Sex, and Heart Rate on Corrected QT Interval Values Calculated by Using Bazett and Fridericia Formulas in Children and Young Adolescent Athletes. Clin J Sport Med. 2025.
  10. Schwartz PJ, Ackerman MJ, George AL, Wilde AAM. Impact of Genetics on the Clinical Management of Channelopathies. J Am Coll Cardiol. 2013;62(3):169-180.
  11. Shen WK, Sheldon RS, Benditt DG, et al. 2017 ACC/AHA/HRS Guideline for the Evaluation and Management of Patients With Syncope. J Am Coll Cardiol. 2017;70(5):e39-e110.
  12. Schwartz PJ, Crotti L. Long QT Syndrome. N Engl J Med. 2025;393(20):2023-2034.
  13. Wilde AAM, Semsarian C, Marquez MF, et al. European Heart Rhythm Association/Heart Rhythm Society/APHRS/LAHRS Expert Consensus Statement on the State of Genetic Testing for Cardiac Diseases. Heart Rhythm. 2022;19(7):e1-e60.
  14. Al-Khatib SM, Stevenson WG, Ackerman MJ, et al. 2017 AHA/ACC/HRS Guideline for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death. Heart Rhythm. 2018;15(10):e73-e189.
  15. Shah MJ, Silka MJ, et al. 2021 PACES Expert Consensus Statement on the Indications and Management of Cardiovascular Implantable Electronic Devices in Pediatric Patients. Heart Rhythm. 2021;18(11):1888-1924.
  16. Silka MJ, Shah MJ, et al. 2021 PACES Expert Consensus Statement: Executive Summary. Heart Rhythm. 2021;18(11):1925-1950.
  17. Tisdale JE, Chung MK, Campbell KB, et al. Drug-Induced Arrhythmias: A Scientific Statement From the American Heart Association. Circulation. 2020;142(15):e214-e233.
  18. Page RL, O'Bryant CL, Cheng D, et al. Drugs That May Cause or Exacerbate Heart Failure: A Scientific Statement From the American Heart Association. Circulation. 2016;134(6):e32-69.
  19. Warrings W, Taurines R, Egberts K, et al. Correlation Between Escitalopram, Sertraline, and Fluoxetine Serum Levels and QTc Interval Prolongation in Children and Adolescents. Ther Drug Monit. 2025.

Related Calculators

QTc IntervalCardiology